Navigation Links
Marshall Edwards Receives Positive Response From NASDAQ
Date:3/16/2011

SAN DIEGO, March 16, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has received a positive response from the NASDAQ Listing Qualifications Panel indicating that the Company's request for a transfer and continued listing on The NASDAQ Capital Market has been granted pending verification by the Listing Qualifications Staff. The Company's securities will begin trading on The NASDAQ Capital Market effective with the open of business today, March 16, 2011.

The NASDAQ Capital Market is a continuous trading market that operates in substantially the same manner as The NASDAQ Global Market. All companies listed on The NASDAQ Capital Market must meet certain financial requirements and comply with NASDAQ's corporate governance requirements. The transfer of the Company's listing from The NASDAQ Global Market to The NASDAQ Capital Market should have no impact on trading in the Company's shares, and the Company's stock will continue to trade on NASDAQ under the symbol MSHL.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards to Host Annual Meeting of Stockholders
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
4. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
5. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
6. Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products
7. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
8. China Botanic Pharmaceutical Receives a Tax Exemption in 2011
9. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
10. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
11. Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CITY, Calif. , March 28, 2017 /PRNewswire/ ... company focused on the development and commercialization of ... pain, announced that the European Medicines Agency (EMA) ... sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) ... of the MAA is underway. The MAA for ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... and services, is proud to announce it has joined the National Association for ... the interests of chronically ill, disabled, and dying Americans of all ages and ...
(Date:3/28/2017)... ... 2017 , ... Z-Medica, LLC, a leading developer and marketer ... will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 schools ... by the American College of Surgeons, U.S. Department of Defense, Department of Homeland ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 2017 , ... With less than 10,000 dermatologists in the United States and ... limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... online, today released its inaugural survey on the State of Acne in America. ...
Breaking Medicine News(10 mins):